180 Life Sciences Corp.
ATNF
$2.00
$0.010.50%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.49M | 2.43M | 2.76M | 4.01M | 5.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.45M | 3.54M | 3.68M | 4.80M | 5.64M |
| Operating Income | -1.45M | -3.54M | -3.68M | -4.80M | -5.64M |
| Income Before Tax | -1.23M | -12.61M | -3.68M | -4.76M | -22.69M |
| Income Tax Expenses | -4.40K | -2.35M | -- | -- | -942.70K |
| Earnings from Continuing Operations | -1.23M | -10.27M | -3.68M | -4.76M | -21.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.23M | -10.27M | -3.68M | -4.76M | -21.74M |
| EBIT | -1.45M | -3.54M | -3.68M | -4.80M | -5.64M |
| EBITDA | -1.43M | -3.51M | -3.65M | -4.78M | -5.60M |
| EPS Basic | -1.97 | -24.53 | -13.37 | -24.15 | -185.16 |
| Normalized Basic EPS | -1.44 | -5.30 | -8.35 | -15.09 | -24.85 |
| EPS Diluted | -1.97 | -24.53 | -13.37 | -24.15 | -185.16 |
| Normalized Diluted EPS | -1.44 | -5.30 | -8.35 | -15.09 | -24.85 |
| Average Basic Shares Outstanding | 622.90K | 418.50K | 275.30K | 197.20K | 117.40K |
| Average Diluted Shares Outstanding | 622.90K | 418.50K | 275.30K | 197.20K | 117.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
